Participants at the BioHabana 2022 International Congress highlighted the effectiveness of Jusvinza in the care of severe and critical patients with COVID-19, particularly women in the third trimester of gestation, by inhibiting the hyperinflammation inherent to the systemic disease.

Unless a new strain begins to spread around the world and reaches Cuba -and it does not seem very likely, for now- and the immunity rates of the population begin to fall -and work is being done to prevent this from happening-, in the coming weeks the level of confirmed cases and deaths from COVID-19 should remain stable -and with a tendency to decline-.

Cuba studied a total of 6,676 samples for surveillance during the day, resulting positive 191 for 2.9% positivity. The country accumulates 13,700,787 samples taken and 1,102,750 positive (8.1%).

The Center for Molecular Immunology (CIM) is organizing, along with the Cuban public health ministry, the logistics and health personnel for Phase III and IV clinical trials with the drug NeuroEpo in Alzheimer's patients.

After a week of scientific exchanges and presentation of the main results of Cuban biotechnology in the resolution of social and economic problems, the BioHabana 2022 International Congress concludes today in Havana.

Real world results of the Cuban lung cancer vaccine CIMAvax-EGF confirmed favorable data about safety and effectiveness in prior tests, said Doctor Tania Crombet, directorof clinical research at the Molecular Immunology Center.

Representatives of the Cuban Finlay Vaccines Institute (IFV) and the Swiss-Italian ADDIENNE Pharma&Biotech signed a cooperation accord Thursday in Havana to develop, bottle and commercialize the Cuban COVID-19 Vaccine SOBERANA 02 in Italy.

The results of clinical trials of CIMAvax-EGF, the Cuban vaccine against lung cancer developed between the Center for Molecular Immunology and the Roswell Park Institute of the United States, will be presented today at the International Congress BioHabana 2022.

Foreign researchers attending the International Congress BioHabana 2022 highlighted today Cuba's progress in the field of biotechnology.

The director of Bio-Medical Research at Cuba’s Genetic Engineering and Biotech Center, Gerardo Guillen, said the clinical tests phase I and II for homegrown intra-nasal COVID-19 vaccine MAMBISA were successful.

Dominica’s Prime Minister Roosevelt Skerrit acknowledged on Tuesday the achievements of Cuban biotechnology despite the impact of the US economic, commercial and financial blockade of the island nation for over 60 years.

Dr. Francisco Duran Garcia, national director of epidemiology of the Cuban ministry of public health ( MINSAP by its Spanish acronym), highlighted today the work and comprehensive management that have allowed Cuba to better control the COVID-19 pandemic.

Cuba studied a total of 4,996 samples for surveillance during the day, 196 were positive, for a 3.9% positivity rate. The country accumulates 13,679,899 samples taken and 1,102, 164 positive.

Cuba and El Salvador signed in Havana a memo of understanding to train health specialists from that central American nation, which is considered an initiative that will help deepening bilateral cooperation links between the two countries.